GLP-1 Agonists and Eye Health

Diabetic retinopathy occurs when high blood sugar damages the tiny blood vessels in your retina over time. If you already have this condition, starting a GLP-1 medication may cause it to worsen temporarily, especially if your blood sugar drops rapidly. This phenomenon is called early worsening and typically happens within the first few months of treatment.

We monitor patients with pre-existing retinopathy very closely when they begin GLP-1 therapy. While the long-term benefits of better blood sugar control usually outweigh this short-term risk, we may recommend a more gradual medication start or closer follow-up visits. Some patients experience bleeding in the retina, swelling, or growth of abnormal blood vessels during this adjustment period.

Risk factors for early worsening include:

• High baseline A1C and long-standing diabetes
• Large and rapid A1C reduction, such as more than 2 percentage points within 3 to 6 months
• Existing diabetic macular edema or moderate to severe nonproliferative retinopathy
• Current insulin therapy, high blood pressure, or kidney disease

When these factors are present, we often add an extra eye check about 3 months after GLP-1 initiation or dose increase.

NAION is a serious condition where blood flow to the optic nerve suddenly decreases, causing vision loss. Recent studies have noted a possible association between GLP-1 agonist use and increased NAION risk, though researchers are still working to understand this connection fully. The current evidence is observational and mixed, so a direct causal relationship has not been established. This condition typically causes sudden, painless vision loss in one eye.

• NAION often occurs upon waking and may present as a dark area in your visual field
• The optic nerve swelling can be detected during a dilated eye exam
• Risk appears higher in patients with certain cardiovascular factors
• This condition requires immediate medical attention to assess and manage

Most patients taking GLP-1 medications will never develop NAION. The absolute risk is low. If symptoms suggest NAION, seek same-day evaluation.

Factors linked to higher NAION risk include:

• Age over 50 and a small cup-to-disc ratio, sometimes called disc at risk
• Obstructive sleep apnea or nocturnal blood pressure dips
• High blood pressure, diabetes, high cholesterol, and smoking
• Concurrent use of medications linked to NAION risk, such as PDE5 inhibitors

Do not stop your GLP-1 medication without speaking to your prescribing clinician and eye doctor first.

When you start GLP-1 therapy and glucose control improves, we sometimes see changes consistent with diabetic retinopathy progression. These can include leakage, capillary nonperfusion, or reduced flow in small vessels. These changes are most often related to the speed of glycemic improvement rather than a direct drug effect.

Patients with longstanding diabetes or high blood pressure face greater risk for these vascular complications. The combination of pre-existing vessel damage and the metabolic shifts from GLP-1 therapy can create conditions where your retinal circulation struggles. Regular monitoring allows us to intervene early if we detect concerning patterns. Long-term data suggest neutral or possibly favorable microvascular outcomes with good glucose control, but careful monitoring remains important during the early phases of therapy.

Beyond the serious complications, some patients notice temporary vision changes when starting GLP-1 medications. Blurred vision is among the most common complaints and usually improves as your body adjusts to better blood sugar levels. The lens inside your eye can swell or shrink slightly as glucose levels change, temporarily affecting your focus.

• Fluctuating vision that varies throughout the day, especially during dose adjustments
• Difficulty with your usual reading glasses or contact lens prescription
• Mild light sensitivity or glare that resolves over several weeks
• Dry eye symptoms that may be managed with artificial tears

If you need a new glasses prescription, wait until your blood sugar has been stable for 6 to 8 weeks. This reduces the chance of a temporary refractive change that would make your new prescription inaccurate.

Before starting GLP-1 therapy, we recommend a comprehensive dilated eye examination to establish your baseline eye health. This examination documents any existing diabetic retinopathy, macular changes, optic nerve appearance, and overall retinal health. Having this baseline allows us to detect new changes more accurately during treatment. Schedule this baseline exam ideally within 3 months before starting therapy, or within 4 to 6 weeks after the first dose if a pre-start exam is not feasible.

Your eye doctor will measure your vision, check eye pressure, and carefully examine all structures of your eye after dilation. We take detailed notes and often capture photographs of your retina for future comparison. If we find significant diabetic eye disease, we discuss this with your prescribing physician to coordinate the safest treatment plan. In some situations, we may recommend treating existing eye problems before you begin GLP-1 medication.

A diabetic eye screening involves several steps to thoroughly evaluate your retinal health. After dilating your pupils with eye drops, we examine your retina using specialized lenses and bright lights. The dilation takes about 20 to 30 minutes to take full effect and will blur your vision for several hours afterward, so plan to have someone drive you home.

• Visual acuity testing to measure how clearly you see at various distances
• Pupil dilation using drops that temporarily enlarge your pupils
• Detailed retinal examination looking for bleeding, swelling, or abnormal vessels
• Optic nerve evaluation to assess its color, shape, and blood supply
• Discussion of findings and recommended follow-up timing

Your follow-up examination frequency depends on your baseline eye health and how your body responds to GLP-1 treatment. Patients without diabetic retinopathy at baseline typically need exams every 12 months, though we may recommend more frequent visits during the first year of therapy. Those with existing eye disease usually require examinations every 3 to 6 months, especially when first starting medication or adjusting doses.

We may modify your follow-up schedule based on your blood sugar changes and any eye findings we detect. If your hemoglobin A1C drops quickly or we see early signs of retinopathy worsening, we increase monitoring frequency. Close communication between our office and your diabetes care team ensures we catch problems early. Never skip a scheduled eye appointment, even if your vision feels fine, because many diabetic eye changes cause no symptoms until they become advanced.

Typical monitoring intervals:

• No diabetic retinopathy at baseline: recheck at 6 to 12 months, with one visit at about 6 months if A1C is dropping quickly
• Mild nonproliferative diabetic retinopathy: every 6 months, or at 3 months if A1C reduction exceeds 2 percentage points
• Moderate to severe nonproliferative diabetic retinopathy or any diabetic macular edema: every 3 months and consider retina specialist co-management
• Proliferative retinopathy or treated diabetic macular edema: follow the retina specialist schedule

Advanced imaging technology helps us detect subtle changes in your retina before they affect your vision. Optical coherence tomography, or OCT, creates detailed cross-sectional images of your retinal layers, revealing swelling or fluid accumulation invisible during standard examination. This painless test takes only a few minutes and provides valuable information about your macular health. OCT also helps quantify macular thickness over time to guide treatment decisions.

We may also use fundus photography to document the appearance of your retina over time, creating a visual record of any changes. Fluorescein angiography, where we inject a safe dye and photograph its flow through your retinal blood vessels, helps us identify leaking or blocked vessels. Optical coherence tomography angiography, or OCTA, maps your retinal circulation without requiring injections. Your eye doctor selects the most appropriate imaging based on your individual situation.